Cardinal Health Says It Now Exclusively Serves Nearly Half The Cell-And-Gene Therapy Market

기사 요약

CAH stock hits new 52-week high as Cardinal Health beats Q4 earnings, boosts FY27 outlook, and approves a $5B buyback expansion.